These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752 [TBL] [Abstract][Full Text] [Related]
23. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study. Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596 [TBL] [Abstract][Full Text] [Related]
24. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873 [TBL] [Abstract][Full Text] [Related]
25. Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease. Hadjihambi A; De Chiara F; Hosford PS; Habtetion A; Karagiannis A; Davies N; Gourine AV; Jalan R Hepatology; 2017 Apr; 65(4):1306-1318. PubMed ID: 28066916 [TBL] [Abstract][Full Text] [Related]
27. Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension. Jalan R; De Chiara F; Balasubramaniyan V; Andreola F; Khetan V; Malago M; Pinzani M; Mookerjee RP; Rombouts K J Hepatol; 2016 Apr; 64(4):823-33. PubMed ID: 26654994 [TBL] [Abstract][Full Text] [Related]
28. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)]. Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Blanco Vela CI; Poo Ramírez JL Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883 [TBL] [Abstract][Full Text] [Related]
31. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791 [TBL] [Abstract][Full Text] [Related]
32. [Prevention and treatment of hepatic encephalopathy]. Sivolap YP Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503 [TBL] [Abstract][Full Text] [Related]
33. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Haj M; Rockey DC Am J Gastroenterol; 2020 May; 115(5):723-728. PubMed ID: 31658104 [TBL] [Abstract][Full Text] [Related]
34. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders. Longo N; Diaz GA; Lichter-Konecki U; Schulze A; Inbar-Feigenberg M; Conway RL; Bannick AA; McCandless SE; Zori R; Hainline B; Ah Mew N; Canavan C; Vescio T; Kok T; Porter MH; Berry SA Mol Genet Metab; 2021 Jan; 132(1):19-26. PubMed ID: 33388234 [TBL] [Abstract][Full Text] [Related]
35. Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study. Weiss N; Tripon S; Lodey M; Guiller E; Junot H; Monneret D; Mayaux J; Brisson H; Mallet M; Rudler M; Imbert-Bismut F; Thabut D; Fundam Clin Pharmacol; 2018 Apr; 32(2):209-215. PubMed ID: 29239015 [TBL] [Abstract][Full Text] [Related]
36. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes. Rahimi RS; Brown KA; Flamm SL; Brown RS Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619 [TBL] [Abstract][Full Text] [Related]
37. Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration. Ghabril M; Zupanets IA; Vierling J; Mantry P; Rockey D; Wolf D; O'Shea R; Dickinson K; Gillaspy H; Norris C; Coakley DF; Mokhtarani M; Scharschmidt BF Clin Pharmacol Drug Dev; 2013 Jul; 2(3):278-84. PubMed ID: 27121790 [TBL] [Abstract][Full Text] [Related]